Sign in
Taking peoplePhase 4

Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)

Key facts

Who runs it
Copenhagen Respiratory Research
Where
Denmark14 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
1,600 people, planned
Started
10 Mar 2026
Expected to end
1 Nov 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Methylprednisolone (drug)
  • hydrocortisone
Record updated
18 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Age > 18 years
  • Diagnosis of severe CAP for who the physician in charge decides for corticosteroid therapy for severe CAP

Who cannot take part

  • Intolerance to either study drug
  • Active tuberculosis or fungal infection
  • Admitted >24 h
  • Pregnant or breastfeeding women
  • Pneumonia caused by influenza

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP). The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 18 years old diagnosed with severe CAP. The main question is whether there is a difference in all cause mortality within thirty days.

Read full original descriptionShow less

Participants will be randomized to receive treatment with either hydrocortisone or prednisolone.

The 2 groups in the trial

  • Treatment with Hydrocortisone.Existing treatment, for comparison

    This arm will recieve a dose of 200 mg of Hydrocortisone intravenously once daily for five days.

    Treatment: hydrocortisone

  • Treatment with MethylprednisoloneExisting treatment, for comparison

    This arm will recieve a dose of 40 mg of Methylprednisolone intravenously once daily for five days.

    Treatment: Methylprednisolone (drug)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
18 March 2026